Last reviewed · How we verify

NCT05213923

ED Tracking Sheet Implementation

Completed NA Last updated 19 May 2023
What this trial tests

NA trial testing ED Sepsis Tracking Sheet in Sepsis in 194 participants. Completed in 1 June 2022.

Timeline
1 July 2021
Primary endpoint
1 June 2022
1 June 2022

Quick facts

Lead sponsorDartmouth-Hitchcock Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment194
Start date1 July 2021
Primary completion1 June 2022
Estimated completion1 June 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

18 and older, any sex, with Sepsis or Severe Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess whether implementation of an ED Sepsis Tracking Sheet effects the percentage of goal-directed sepsis criteria met in a tertiary care academic Emergency Department.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other Dartmouth-Hitchcock Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05213923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing